Industry News
Biotechnology Industry News
Ikena and Inmagene have selected…
Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger. Yarema comes from a recent career at Poseida, culminating in CEO before the company was bought
Eli Lilly is walking through the…
Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small-molecule drug class.
Australian life sciences venture…
Australian life sciences venture capital firm Brandon Capital has closed its largest fund yet, raising A$439 million (about $290 million) for the sixth Brandon BioCatalyst Fund. The heaps of cash will go toward fast-growing companies
Novartis is serving up $60 million…
Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult to treat.
After ditching a plan to split…
After ditching a plan to split into two distinct companies, Belgian biotech Galapagos is trimming its pipeline and consolidating cell therapies to prep the business unit for a potential sale.
Adicet Bio is handing out pink…
Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing a clinical-stage allogeneic cell therapy.
Rocket Pharmaceuticals is laying…
Rocket Pharmaceuticals is laying off 30% of its staff and focusing on its cardiovascular disease programs, causing delays to assets including a gene therapy that was on track to win approval next year.
A phase 3 study of AstraZeneca’s…
A phase 3 study of AstraZeneca’s gefurulimab has hit its primary and all secondary endpoints, teeing up talks with regulators about the potential blockbuster generalized myasthenia gravis treatment.
Roche has axed one of the obesity…
Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics buyout, sending the molecule to the scrap heap months after hyping its potential to drive weight loss past the GLP-1 plateau.
TCG Labs Soleil has secured $400…
TCG Labs Soleil has secured $400 million to boost the firm’s ability to advance its biotech portfolio companies while also expanding its R&D capabilities globally.
Arrowhead Pharmaceuticals has…
Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that it expects its troubled R&D partner to meet its financial obligations.
After a long, cash-strapped…
After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.
Dispatch Bio has unveiled with…
Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach.
Decentralized Clinical Trials…
Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.
Scancell has linked iSCIB1+ to a…
Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the British biotech to advance the next-generation cancer vaccine candidate rather than its older sibling.
The FDA has rejected Replimune’s…
The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to receive complete response letters from the new-look agency. Investors sent the biotech’s share price
Apnimed has scored another phase 3…
Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the number of nightly breath-stopping events by 46.8%, hitting the test's primary endpoint.
Choosing the right specialty…
Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, therapy fulfillment and generalized patient care.
The Fierce Biotech Fundraising…
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
As always, if you know of layoffs…
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.